---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-027307"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2026-06-04T21:01:23+00:00"
generated_at: "2026-06-04T21:17:31.568828+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lixte Biotechnology closes ~$16.6M registered direct offering of common stock and warrants

## Summary
- Gross proceeds of ~$16.6 million from sale of 2,625,362 shares and pre-funded warrants.
- Offering priced at $6.31 per common share and $6.3099 per pre-funded warrant.
- Pre-funded warrants exercisable immediately at $0.0001 per share.
- Net proceeds to be used for general corporate purposes and working capital.
- Offering closed on June 4, 2026 under existing shelf registration statement.

## SEC filing metadata
- accession: 0001493152-26-027307
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2026-06-04T21:01:23+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315226027307/0001493152-26-027307-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315226027307/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-027307
- JSON: https://secwatch.observer/filing/0001493152-26-027307.json
- Plain text: https://secwatch.observer/filing/0001493152-26-027307.txt

## Key facts
- Material Agreements
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into Purchase Agreement with certain accredited investors valued at approximately $16.6 million (effective 2026-06-02).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $16.6 million
  - Effective: 2026-06-02
  source text: On June 2, 2026, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 2,366,503 shares (the “Common Shares”) of the Company’s Common Stock, par value $0.0001 per share (the “Common Stock”), and Pre-Funded Warrants (“Pre-Funded Warrants”) to purchase 258,859 shares of Common Stock, at an offering price of $6.31 per share (or $6.30 per Pre-Funded Warrant).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000149315226027307/0001493152-26-027307-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.